ethyl (1R,2R)-2-acetylcyclopropane-1-carboxylate | 1231941-58-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl (1R,2R)-2-acetylcyclopropane-1-carboxylate
• CAS: 1231941-58-4
• 化学式: C₈H₁₂O₃
• 分子量: 156.181
• InChiKey: JWHOQERPMUIEOY-NKWVEPMBSA-N

物化性质

• 沸点：
  210.5±33.0 °C(Predicted)
• 密度：
  1.126±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl (1R,2R)-2-acetylcyclopropane-1-carboxylate 在 盐酸 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 乙醚 、 正戊烷 、 苯 为溶剂， 反应 21.0h， 生成 trans-1-[2-(1-hydroxy-1-methylethyl)cyclopropyl]ethanone
  参考文献：
  名称：

  Regiospecific preparation of 2-(carbomethoxy)-4-methylcyclohept-4-enone via the divinylcyclopropane rearrangement

  摘要：

  DOI：

  10.1021/jo00322a034
• 作为产物：
  描述：

  反-1,2-环丙烷二羧酸二乙酯 在 sodium hydroxide 、 copper(l) iodide 、 氯化亚砜 作用下， 以 乙醇 为溶剂， 反应 7.5h， 生成 ethyl (1R,2R)-2-acetylcyclopropane-1-carboxylate
  参考文献：
  名称：

  2-Substituted (2SR)-2-Amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as Potent and Selective Antagonists of Group II Metabotropic Glutamate Receptors. 1. Effects of Alkyl, Arylalkyl, and Diarylalkyl Substitution

  摘要：

  In this paper, we describe the synthesis of a series of a-substituted analogues of the potent and selective group II metabotropic glutamate receptor (mGluR) agonist (1S,1'S,2'S)-carboxy-cyclopropylglycine (2, L-CCG 1). Incorporation of a substituent on the amino acid carbon converted the agonist 2 into antagonist. Ail of the compounds were prepared and tested as a series of four isomers, i.e., two racemic diastereomers. We explored alkyl substitution, both normal and terminally branched; phenylalkyl and diphenylalkyl substitution; and a variety of aromatic and carbocyclic surrogates for phenyl. Affinity for group II mGluRs was measured using [H-3]glutamic acid (Glu) binding in rat forebrain membranes. Antagonist activity was confirmed for these compounds by measuring their ability to antagonize (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid-induced inhibition of forskolin-stimulated cyclic-AMP in RGT cells transfected with human mGluR2 and mGluR3. We found that while alkyl substitution provided no increase in affinity relative to 2, phenylethyl and diphenylethyl substitution, as in 105 and 109, respectively, were quite beneficial, The affinity of 109 was further enhanced when the two aromatic rings were joined by an oxygen or sulfur atom to form the tricyclic xanthylmethyl and thioxanthylmethyl amino acids 113 and 114, respectively. Amino acid 113, with an IC50 of 0.10 mu M in the [H-3]Glu binding assay, was 52-fold more patent than 2, whose IC50 was 0.47 mu M.

  DOI：

  10.1021/jm970497w

文献信息

• SOLUBLE GUANYLATE CYCLASE STIMULATORS
  申请人：Berger Raphaelle

  公开号：US20170174693A1

  公开（公告）日：2017-06-22

  The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R 1 , R 2 , R 4 , R a , and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

  该发明提供了Formula (I)的化合物或其药用盐，其中X、Y、Z、R1、R2、R4、Ra以及下标m、p和q如本文所述。这些化合物或其药用盐可以调节人体对环鸟苷酸单磷酸（“cGMP”）的产生，并通常适用于治疗和预防与扰乱的cGMP平衡相关的疾病。该发明还提供了包含Formula (I)的化合物或其药用盐的药物组合物。该发明还涉及使用这些化合物或其药用盐在治疗和预防上述疾病以及为此目的制备药物的方法。
• [EN] SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE<br/>[FR] AMINO-TRIAZOLOPYRIMIDINE ET AMINO-TRIAZOLOPYRAZINE SUBSTITUÉS ANTAGONISTE DU RÉCEPTEUR DE L'ADÉNOSINE, COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2020106558A1

  公开（公告）日：2020-05-28

  In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): or and pharmaceutically acceptable salts thereof, wherein, R1, R2, and R3 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

  在其多种实施方式中，本发明提供了某些Formula (IA)和Formula (IB)的取代氨基三唑吡啶和氨基三唑吡嗪化合物，或其药学上可接受的盐，其中，R1、R2和R3如本文所定义，包括一种或多种这样的化合物的药物组合物（单独或与一种或多种其他治疗活性剂的组合），以及其制备和使用的方法，单独或与其他治疗剂的组合，作为A2a和/或A2b受体的拮抗剂，并且它们在治疗由腺苷A2a受体和/或腺苷A2b受体至少部分介导的各种疾病、症状或紊乱中的用途。
• Catalytic cyclopropanation of electron deficient alkenes mediated by chiral and achiral sulfides: scope and limitations in reactions involving phenyldiazomethane and ethyl diazoacetate
  作者：Varinder K. Aggarwal、Helen W. Smith、George Hynd、Ray V. H. Jones、Robin Fieldhouse、Sharon E. Spey

  DOI：10.1039/b004367m

  日期：——

  Phenyldiazomethane reacts with electron deficient alkenes in the presence of catalytic amounts of transition metal catalyst [Rh2(OAc)4 was better than Cu(acac)2] and catalytic amounts of sulfide to give cyclopropanes. Pentamethylene sulfide was found to be superior to tetrahydrothiophene and the optimum solvent was toluene. Under these optimised conditions a range of enones were cyclopropanated in

  苯重氮甲烷 与电子缺乏反应 烯烃 在催化量的过渡金属存在下 催化剂[Rh 2（OAc）4优于Cu（acac）2 ]和硫化物的催化量得到环丙烷。 五甲基亚砜 被发现优于 四氢噻吩 和最佳 溶剂 曾是 甲苯。在这些优化条件下，烯酮进行了高产率的环丙烷化。循环的烯酮丙烯酸酯在此过程中不成功。衍生自手性的1,3-氧杂蒽的用途樟脑磺酰氯 在此过程中分两步进行 环丙烷具有良好的收率和很高的对映体过量（> 97％ee）。的绝对立体化学环丙烷 10被证明X射线分析立体化学诱导的来源已经合理化。这项工作扩展到包括重氮酯，是部分成功的。再次五亚甲基硫醚 被发现优于 四氢噻吩，但这次发现Rh 2（OAc）4和Cu（acac）2都同样有效。烯酮，富马酸和不饱和 硝基化合物 效果很好，但简单的丙烯酸酯和不饱和丙烯酸酯 醛类不是有效的底物。进行了对照实验，其中稳定的叶立德 分离并与不太成功的底物反应，而不饱和 醛类
• On the Mechanism of Ylide-Mediated Cyclopropanations: Evidence for a Proton-Transfer Step and Its Effect on Stereoselectivity
  作者：Samantha L. Riches、Chandreyee Saha、Noelia Fontán Filgueira、Emma Grange、Eoghan M. McGarrigle、Varinder K. Aggarwal

  DOI：10.1021/ja910631u

  日期：2010.6.9

  with chiral sulfur ylides. It had previously been found that semi-stabilized sulfonium ylides (e.g., Ph-stabilized) reacted with cyclic and acyclic enones and substituted acrylates with high ee and that stabilized sulfonium ylides (e.g., ester-stabilized) reacted with cyclic enones again with high ee. The current study has focused on the reactions of stabilized sulfonium ylides with acyclic enones

  在本文中，我们描述了迈克尔受体与手性硫叶立德环丙烷化的研究。先前已经发现，半稳定的锍叶立德（例如，Ph-稳定的）与环状和非环状烯酮以及取代的丙烯酸酯反应，具有高 ee 并且稳定的锍叶立德（例如，酯稳定的）再次与具有高 ee 的环烯酮反应. 目前的研究集中在稳定的锍叶立德与无环烯酮的反应上，这些反应出乎意料地降低了 ee。此外，在与甲基乙烯基酮 (MVK) 的反应中观察到 ee 与叶立德稳定性的明显相关性：酮稳定的叶立德产生 25% ee，酯稳定的叶立德产生 46% ee，酰胺稳定的叶立德产生 89% ee。据信，甜菜碱形成后，会出现一个不寻常的质子转移步骤，这会损害该过程的对映选择性。因此，在将稳定的叶立德添加到迈克尔受体后，甜菜碱中间体内的快速和可逆的分子内质子转移，在闭环之前，导致 ee 的侵蚀。最稳定的叶立德（酮）发生最大程度的质子转移。当用氘标记的锍叶立德进行相同的反应时，在所有情况下都观察到更高的
• HETEROCYCLIC INHIBITORS OF GLUTAMINASE
  申请人：Calithera Biosciences Inc.

  公开号：US20130157998A1

  公开（公告）日：2013-06-20

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.

  本发明涉及新型杂环化合物及其制药制剂。本发明还涉及使用所述新型杂环化合物治疗的方法。